Real-World study tests Three-Drug combo for multiple myeloma
NCT ID NCT06933277
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This study is tracking how well a combination of three drugs—selinexor, bortezomib, and dexamethasone (SVd)—works in everyday medical practice for adults with multiple myeloma who have already received 1 to 3 prior treatments. Researchers will follow 159 patients for about 12 months to see how long the cancer stays under control. The goal is to understand the real-world effectiveness and safety of this treatment outside of clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aou Careggi - Sod Ematologia
RECRUITINGFlorence, Italy
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
selinexor, bortezomib, and dexamethasone (SVd)
What this could lead to
If successful, this study could confirm that SVd works well in everyday medical practice for multiple myeloma patients who have already tried other treatments.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also relatively small (159 patients) and only follows patients for 12 months, which may not capture long-term effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.